NEW YORK--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced the successful initial safety results of two Phase I clinical trials of the company’s first product, Vascugel™. The trials were designed to study the safety of Vascugel™ in maintaining vascular patency in patients with arteriovenous access fistulas (AVF) and arteriovenous access grafts (AVG) for dialysis treatment of end-stage renal disease (ESRD).
